Sources: Iambic: initial public offering pricing; City Therapeutics: upsized IPO pricing; SEC Investor Bulletin: Investing in an IPO
Base gross proceeds at the announced prices
US$ millions, rounded; pricing announcements October 14–15
Sources: [1] Iambic: initial public offering pricing · October 14, 2026; closing expected October 16; [2] City Therapeutics: upsized IPO pricing · October 15, 2026; closing expected October 19
Iambic prices its base offering
Iambic announced October 14 that it priced 9,375,000 shares at $16, producing $150 million of gross proceeds before underwriting costs and expenses. All base-offering shares were offered by the company. Trading under IAM on Nasdaq was expected October 15, with closing expected October 16 subject to conditions. This report verifies the pricing announcement, not a separate closing confirmation or subsequent trading return. The issuer describes itself as a clinical-stage company using an AI-enabled drug-development platform. [1]
City prices an upsized transaction
City Therapeutics announced October 15 that it priced 11,111,111 shares at $18, approximately $200 million gross, with all base shares offered by the company. The RNA interference company expected Nasdaq trading under CTY on October 16 and closing October 19, after this edition's editorial cutoff. The base transaction and optional additional shares are separate amounts. The expected closing date should not be brought forward merely because trading was scheduled to begin earlier. [2]
An effective registration is not an investment endorsement
The SEC's investor bulletin explains that registration review concerns disclosure and does not mean the agency has approved an investment's merits. The offering price is also distinct from the price available to investors once secondary trading begins. The prospectus is the appropriate starting point for examining the securities, proceeds, risks and shareholder arrangements. In these two cases, the arithmetic describes base gross capital: it does not provide net proceeds, market capitalization or the subsequent return earned by someone buying in the public market. [3]
Clinical progress follows a different evidence process
FDA guidance distinguishes stages of clinical research, from initial safety and dosing work through larger studies of benefit and risk. These stages do not become interchangeable because a company has completed a financing. An investigational programme and an approved marketed treatment are different states. The agency's general explanation is used here to frame the evidence required, not to assign either issuer a particular probability of approval. The pricing releases themselves do not establish that a product has demonstrated the clinical results required for authorization. [4]
Sources & methodology
Bracketed numbers refer to the sources below. Analysis is original editorial interpretation, not a personalized recommendation.
- Iambic: initial public offering pricing · October 14, 2026; closing expected October 16
- City Therapeutics: upsized IPO pricing · October 15, 2026; closing expected October 19
- SEC Investor Bulletin: Investing in an IPO · October 14, 2022; standing investor guidance
- FDA: Step 3, Clinical Research · Standing drug-development guidance; reviewed October 18, 2026
